Biogen Inc Price, Chart & Factor Exposure
Free Data & Analytics AccessLatest earnings: October 28, 2026 results vs estimates
Biogen Inc Forecast
Biogen Inc short-term momentum is positive (up over 3 of 4 look-backs: 5, 10, 20 and 30 trading days), a short-term BUY signal. The long-term trend is strongly positive (8 of 8 checks up: price above, and slope of, its 50-, 100-, 150- and 200-day averages), a long-term BUY signal. Based on 20-day realised volatility of 33.6% a year, a typical one-standard-deviation range is 237.82–261.48 over a week, 225.42–273.88 over a month and 165.70–333.60 over a year. (Signals as of 1 Nov 2026.)
Biogen Inc Price Chart
Biogen Inc Factors
YoY +562.3%
YoY +39.9%
YoY +37.7%
YoY +232.7%
YoY +49.3%
YoY −36.7%
YoY −84.9%
YoY +43.1%
YoY +147.1%
YoY +438.3%
YoY −28.4%
YoY −32.8%
YoY −77.5%
YoY +13.9%
YoY −57.1%
YoY −4.4%
Biogen Inc fundamentals: income statement, balance sheet & cash flow
Biogen Inc reported revenue of $9.89bn and net income of $1.29bn in FY2025, the year ended 31 December 2025 — revenue up 2.2% and net income down 20.8% on the prior year. Free cash flow was $2.05bn. These figures are as reported in the filings, not restated: 41 fiscal years and 165 quarters of history, back to December 1985. 173 FINRA short-interest settlements are published alongside them, back to June 2019.
| USD billions | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | 31 Dec 2025 | 31 Dec 2024 | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 |
| Revenue | 9.89 | 9.68 | 9.84 | 10.17 | 10.98 |
| Cost of revenue | 2.40 | 2.31 | 2.53 | 2.28 | 2.11 |
| Gross profit | 7.49 | 7.37 | 7.30 | 7.90 | 8.87 |
| Research & development | 1.78 | 2.49 | 2.70 | 2.60 | 3.40 |
| Operating income | 2.47 | 2.49 | 2.10 | 2.89 | 2.79 |
| EBITDA | 2.60 | 3.00 | 2.38 | 3.54 | 3.92 |
| Interest expense | 0.27 | 0.25 | 0.25 | 0.25 | 0.25 |
| Pre-tax income | 1.56 | 1.91 | 1.30 | 3.59 | 1.78 |
| Income tax | 0.26 | 0.27 | 0.14 | 0.63 | 0.05 |
| Net income | 1.29 | 1.63 | 1.16 | 3.05 | 1.56 |
Download Biogen Inc fundamentals
https://macrofinance.ai/wp-admin/admin-ajax.php?action=mf_fundamentals&symbol=E.BIIB.NASDAQ&statement=all&freq=a&format=csv&years=10
Figures in USD, statements as filed and FINRA consolidated short interest. A cell is left blank where the filing does not report it or where the reported figure fails the statement’s own arithmetic. Short interest is the consolidated FINRA figure for the settlement date shown, published seven to eight business days later.
Research on Biogen Inc
Explore MacroFinance macro & markets research and analysis.
Biogen Inc Trading Strategies
58 backtested tactical asset allocation strategies hold SPY (US market) or XLV (Health Care sector), the closest tradable exposure to Biogen Inc; 28 of them are invested now. Strategies currently invested are listed first.
| Strategy | Style | Rebalance | Now in SPY, XLV | CAGR | Sharpe | Max DD |
|---|---|---|---|---|---|---|
| Tactical Permanent Portfolio | Conservative | Monthly | Premium · upgrade to view | |||
| Zakamulin and Giner's Optimal Trend Following | Moderate | Monthly | Premium · upgrade to view | |||
| Movement Capital's Composite Strategy | Moderate | Monthly | Premium · upgrade to view | |||
| Harry Browne's Permanent Portfolio | Conservative | Monthly | 25% | 7.0% | 0.96 | -17.2% |
| Keller and Van Putten's Flexible Asset Allocation | Moderate | Monthly | Premium · upgrade to view | |||
| Ned Davis' Three Way Model | Moderate | Monthly | Premium · upgrade to view | |||
| 60_40 Benchmark | Moderate | Monthly | 60% | 8.2% | 0.93 | -29.5% |
| Dick Stoken's Active Combined Asset (ACA) - Monthly Trading | Moderate | Monthly | Premium · upgrade to view | |||
| PortfolioCharts' Golden Butterfly | Moderate | Monthly | 20% | 7.4% | 0.91 | -18.0% |
| US Cross-Asset Momentum | Moderate | Monthly | Premium · upgrade to view | |||
Hypothetical backtests over each ETF's own history; past performance does not guarantee future results. Upgrade to see every strategy's allocation and performance.
From creators
- P4 Demo Momentum by admin
- strategyx by admin
Statistical Distribution of Returns
PlusHow Biogen Inc’s returns are distributed — and how they change in a given market regime.
Regime filters
| Market/Macro | Indicator | Criteria | Value | And (for Between) | Action |
|---|
No regime filter yet — the chart below shows every period. Add a factor condition, or pick a popular regime.
| Statistic | All periods | Matching |
|---|
About Biogen Inc (United States)
Biogen Inc is a listed security in the United States. This page shows the latest price and daily change, a price chart, momentum, trend, bubble-risk and volatility signals, its factor exposures, the statistical distribution of its returns, the trading strategies that hold it and free historical data (the last 10 years as CSV or JSON, no login).
Last updated: November 22, 2026
More on Biogen Inc
Frequently asked questions
What is Biogen Inc?
What is the latest Biogen Inc price?
Is Biogen Inc in an uptrend?
How volatile is Biogen Inc?
What factors affect Biogen Inc?
Which trading strategies trade Biogen Inc?
How are Biogen Inc returns analysed?
Where can I download free Biogen Inc historical data?
Free Biogen Inc historical data (last 10 years)
Browse or instantly download the last 10 years of Biogen Inc daily price history. A free account unlocks the full history, an Excel export with factors, and API access.
https://macrofinance.ai/wp-admin/admin-ajax.php?action=mf_history&symbol=E.BIIB.NASDAQ&format=csv&years=10
| Date | Close |
|---|---|
| 2026-11-20 | 249.59 |
| 2026-11-19 | 247.13 |
| 2026-11-18 | 251.41 |
| 2026-11-17 | 250.79 |
| 2026-11-16 | 251.65 |
| 2026-11-13 | 253.4 |
| 2026-11-12 | 250.48 |
| 2026-11-11 | 253.4 |
| 2026-11-10 | 253.25 |
| 2026-11-09 | 254.87 |
About this stock
Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE. It offers LEQEMBI for the treatment of Alzheimer's disease; ZURZUVAE for the treatment of postpartum depression; RITUXAN to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for aRelapsed or refractory diffuse large B-cell lymphoma; and other anti-CD20 therapies. Biogen Inc. has collaboration and license agreements with Merz Therapeutics; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; UCB; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis; and Sage Therapeutics, Inc., as well as collaborations with Stoke Therapeutics, Inc. for the development and commercialization of zorevunersen, a disease modifying medicine for the treatment of Dravet syndrome; Dayra Therapeutics, Inc. to develop oral macrocyclic peptides; Vanqua Bio, Inc. for developing Vanqua's preclinical oral C5aR1 antagonist compound; City Therapeutics, Inc. to develop select novel RNAi therapies; and ALTEOGEN Inc. to develop subcutaneous (SC) formulations of biologics utilizing ALT-B4. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
See how this market's returns behaved when a factor was in a given state, for example when Momentum was strong or bond yields were above 4%, and compare that with all periods.
Reading the chart
- Each bar is a return bucket; its height is the share of periods that landed there.
- All periods: every return in the date range.
- Matching periods: only the periods where all your filters were true. If orange shifts right of the grey, returns were better in that regime.
- Each period's return is the return over the following day, week or month (set by Timeframe), measured from the day the factor was read, so there is no look-ahead.
Adding a filter
- Factor: grouped the same way as the Factors section on this page (Quantitative, Country, Sector, …). Locked factors are listed but greyed out.
- Criteria: greater (>), greater or equal (≥), equal (=), smaller or equal (≤), smaller (<) or between two values.
- Value: depends on the factor.
- Momentum and Trend are signals from −1 to +1, picked as −100 to +100 in steps of 25.
- Mean Reversion is a z-score of price against its 250-day mean, picked in σ from −3 to +3.
- Everything else is a number you type. The line under the box shows the latest reading and its typical range over the last 10 years.
Add several filters to combine conditions; a period must pass every one. Narrow the window with the From/To dates or the 1Y / 5Y / 10Y / MAX buttons; Clear resets filters and dates.
Return statistics
- Unfiltered vs Filtered: all periods vs matching periods.
- Average return, Std dev and Sharpe are annualised (252 days, 52 weeks, 12 months, 6 two-month periods, 4 quarters).
- Maximum drawdown compounds non-overlapping periods; in the Filtered column it assumes you held only while the condition was true.
- Min, 25th percentile, median, 75th percentile and max are per period, not annualised.